Frequent hepatitis C virus superinfection in injection drug users

被引:57
作者
Herring, BL
Page-Shafer, K
Tobler, LH
Delwart, EL
机构
[1] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94118 USA
[2] Univ Calif San Francisco, Dept Med, San Francisco, CA 94118 USA
[3] Univ Calif San Francisco, Ctr AIDS Prevent Studies, San Francisco, CA 94118 USA
关键词
D O I
10.1086/424491
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The frequency of hepatitis C virus (HCV) superinfection with a divergent viral strain was determined in a cohort of recently infected young injection drug users (IDUs) with an HCV incidence rate of 25%. HCV was amplified, by use of polymerase chain reaction (PCR), from plasma samples collected from 25 HCV-infected individuals over an average period of 12 months, and their viral sequences were compared. Phylogenetic analysis identified 5 IDUs with superinfection (20%) occurring after seroconversion: 2 IDUs were superinfected with different HCV genotypes, and 3 were superinfected with divergent strains of the same genotype. The superinfecting strains were not detected as minority variants (<0.5%) in the initial plasma HCV quasi species. Extensive measures were taken to exclude PCR contamination and mix-up of samples, and superinfection results were concordant at 2 HCV genetic loci. HCV superinfection in IDUs, both intra- and intergenotype, is therefore a frequent event, with an incidence rate similar to that of de novo infections. These results suggest that no cross-protecting immunity develops during the first year of chronic infection with HCV.
引用
收藏
页码:1396 / 1403
页数:8
相关论文
共 60 条
[1]   Natural history of hepatitis C [J].
Alberti, A ;
Chemello, L ;
Benvegnù, L .
JOURNAL OF HEPATOLOGY, 1999, 31 :17-24
[2]   The prevalence of hepatitis C virus infection in the United States, 1988 through 1994 [J].
Alter, MJ ;
Kruszon-Moran, D ;
Nainan, OV ;
McQuillan, GM ;
Gao, FX ;
Moyer, LA ;
Kaslow, RA ;
Margolis, HS .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (08) :556-562
[3]   HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus [J].
Altfeld, M ;
Allen, TM ;
Yu, XG ;
Johnston, MN ;
Agrawal, D ;
Korber, BT ;
Montefiori, DC ;
O'Connor, DH ;
Davis, BT ;
Lee, PK ;
Maier, EL ;
Harlow, J ;
Goulder, PJR ;
Brander, C ;
Rosenberg, ES ;
Walker, BD .
NATURE, 2002, 420 (6914) :434-439
[4]  
ASCHER DP, 1993, J ACQ IMMUN DEF SYND, V6, P241
[5]   Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection [J].
Bassett, SE ;
Guerra, B ;
Brasky, K ;
Miskovsky, E ;
Houghton, M ;
Klimpel, GR ;
Lanford, RE .
HEPATOLOGY, 2001, 33 (06) :1479-1487
[6]   A genetic analysis of hepatitis Cvirus transmission between injection drug users [J].
Cochrane, A ;
Searle, B ;
Hardie, A ;
Robertson, R ;
Delahooke, T ;
Cameron, S ;
Tedder, RS ;
Dusheiko, GM ;
de Lamballerie, X ;
Simmonds, P .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (09) :1212-1221
[7]   Analysis of a successful immune response against hepatitis C virus [J].
Cooper, S ;
Erickson, AL ;
Adams, EJ ;
Kansopon, J ;
Weiner, AJ ;
Chien, DY ;
Houghton, M ;
Parham, P ;
Walker, CM .
IMMUNITY, 1999, 10 (04) :439-449
[8]  
De Socio Giuseppe Vittorio Luigi, 1996, Clin Microbiol Infect, V2, P20
[9]   Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia [J].
Eyster, ME ;
Sherman, KE ;
Goedert, JJ ;
Katsoulidou, A ;
Hatzakis, A .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (05) :1062-1069
[10]   LACK OF PROTECTIVE IMMUNITY AGAINST REINFECTION WITH HEPATITIS-C VIRUS [J].
FARCI, P ;
ALTER, HJ ;
GOVINDARAJAN, S ;
WONG, DC ;
ENGLE, R ;
LESNIEWSKI, RR ;
MUSHAHWAR, IK ;
DESAI, SM ;
MILLER, RH ;
OGATA, N ;
PURCELL, RH .
SCIENCE, 1992, 258 (5079) :135-140